NASDAQ:PEPG - US7133171055 - Common Stock
The current stock price of PEPG is 1.4 USD. In the past month the price increased by 22.81%. In the past year, price decreased by -85.23%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.98 | 373.87B | ||
AMGN | AMGEN INC | 12.77 | 149.94B | ||
GILD | GILEAD SCIENCES INC | 14.89 | 143.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.94 | 99.62B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.52B | ||
REGN | REGENERON PHARMACEUTICALS | 12.18 | 58.91B | ||
ARGX | ARGENX SE - ADR | 82.3 | 46.69B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.49 | 37.32B | ||
INSM | INSMED INC | N/A | 30.85B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.28B | ||
NTRA | NATERA INC | N/A | 23.30B | ||
BIIB | BIOGEN INC | 8.91 | 20.91B |
PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
PEPGEN INC
245 Main St, 2nd Floor
Cambridge MASSACHUSETTS US
Employees: 62
Phone: 17034568000
The current stock price of PEPG is 1.4 USD. The price decreased by -5.41% in the last trading session.
The exchange symbol of PEPGEN INC is PEPG and it is listed on the Nasdaq exchange.
PEPG stock is listed on the Nasdaq exchange.
11 analysts have analysed PEPG and the average price target is 7.14 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.4. Check the PEPGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PEPGEN INC (PEPG) has a market capitalization of 45.92M USD. This makes PEPG a Nano Cap stock.
PEPGEN INC (PEPG) currently has 62 employees.
PEPGEN INC (PEPG) has a support level at 1.24 and a resistance level at 1.41. Check the full technical report for a detailed analysis of PEPG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PEPG does not pay a dividend.
PEPGEN INC (PEPG) will report earnings on 2025-11-05.
PEPGEN INC (PEPG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.96).
The outstanding short interest for PEPGEN INC (PEPG) is 4% of its float. Check the ownership tab for more information on the PEPG short interest.
ChartMill assigns a technical rating of 5 / 10 to PEPG. When comparing the yearly performance of all stocks, PEPG is a bad performer in the overall market: 96% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PEPG. PEPG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months PEPG reported a non-GAAP Earnings per Share(EPS) of -2.96. The EPS increased by 9.97% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -94.79% | ||
ROE | -136.2% | ||
Debt/Equity | 0 |
11 analysts have analysed PEPG and the average price target is 7.14 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.4.